Shorrem Naeem
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shorrem Naeem has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Zainab Arif
Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan
2 shared publications - Erum Siddiqui
Jinnah Sindh Medical University, Karachi, Pakistan
1 shared publication - Hafsa Ali
Sindh Medical College Jinnah Sindh Medical University Karachi Pakistan
1 shared publication - Mohammed Hammad Jaber Amin
Faculty of Medicine Alzaiem Alazhari University Khartoum Sudan
1 shared publication
Latest Publications
- Open Access
- 13 April 2026
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 14 (4) , e70439
Safety and Efficacy of Obinutuzumab in Treating Lupus Nephritis: A Systematic Review
Background: Lupus nephritis (LN) is a serious manifestation of systemic lupus erythematosus (SLE), often leading to end‐stage renal disease. Despite current immunosuppressive therapies, complete renal remission remains limited. Obinutuzumab, a type II anti‐CD20 monoclonal antibody, offers enhanced B‐cell depletion compared to type I antibodies and may improve renal outcomes in LN. This systematic review evaluates the efficacy and safety of obinutuzumab in treating adult patients with proliferative LN. Methods: This review was registered with PROSPERO (CRD420251074418) and conducted in accordance with the PRISMA guidelines. A comprehensive search of PubMed, Cochrane, Embase, Scopus, and clinical trial registries was conducted through June 2025. Eligible studies were randomized controlled trials (RCTs) comparing obinutuzumab vs. placebo in adult patients with biopsy‐confirmed active LN. Primary outcomes included complete renal response (CRR), proteinuria, and estimated glomerular filtration rate (eGFR). Secondary outcomes included immunological markers and adverse events. Data were synthesized qualitatively due to the limited available trials. Results: Two RCTs (REGENCY 2025 and NOBILITY 2022) with 396 patients met the inclusion criteria. Obinutuzumab significantly improved CRR (46.4% in REGENCY at week 76; 41% in NOBILITY at week 104) and reduced proteinuria (UPCR < 0.5 in 62% vs. 37% in controls). Improvements in eGFR, complement levels (C3 and C4), and anti‐dsDNA titers were also noted. Adverse events occurred at similar rates across groups, although serious infections and infusion reactions were somewhat higher in one trial. No significant increase in mortality was observed. Conclusion: Obinutuzumab appears to be a promising therapy for proliferative LN, offering enhanced renal response and immunological benefits. Its potential for long‐term renal protection and steroid‐sparing effects supports further investigation through large‐scale comparative trials.
- 13 April 2026
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 14 (4) , e70439
Open AccessSafety and Efficacy of Obinutuzumab in Treating Lupus Nephritis: A Systematic Review
Background: Lupus nephritis (LN) is a serious manifestation of systemic lupus erythematosus (SLE), often leading to end‐stage renal disease. Despite current immunosuppressive therapies, complete renal remission remains limited. Obinutuzumab, a type II anti‐CD20 monoclonal antibody, offers enhanced B‐cell depletion compared to type I antibodies and may improve renal outcomes in LN. This systematic review evaluates the efficacy and safety of obinutuzumab in treating adult patients with proliferative LN. Methods: This review was registered with PROSPERO (CRD420251074418) and conducted in accordance with the PRISMA guidelines. A comprehensive search of PubMed, Cochrane, Embase, Scopus, and clinical trial registries was conducted through June 2025. Eligible studies were randomized controlled trials (RCTs) comparing obinutuzumab vs. placebo in adult patients with biopsy‐confirmed active LN. Primary outcomes included complete renal response (CRR), proteinuria, and estimated glomerular filtration rate (eGFR). Secondary outcomes included immunological markers and adverse events. Data were synthesized qualitatively due to the limited available trials. Results: Two RCTs (REGENCY 2025 and NOBILITY 2022) with 396 patients met the inclusion criteria. Obinutuzumab significantly improved CRR (46.4% in REGENCY at week 76; 41% in NOBILITY at week 104) and reduced proteinuria (UPCR < 0.5 in 62% vs. 37% in controls). Improvements in eGFR, complement levels (C3 and C4), and anti‐dsDNA titers were also noted. Adverse events occurred at similar rates across groups, although serious infections and infusion reactions were somewhat higher in one trial. No significant increase in mortality was observed. Conclusion: Obinutuzumab appears to be a promising therapy for proliferative LN, offering enhanced renal response and immunological benefits. Its potential for long‐term renal protection and steroid‐sparing effects supports further investigation through large‐scale comparative trials.
- 15 July 2025
- Published by Elsevier in American Journal of Infection Control
- Vol. 53 (8) , 910
“Letter to the editor: Artificial intelligence (AI) use for personal protective equipment training, remediation, and education in health care”
- 15 July 2025
- Published by Elsevier in American Journal of Infection Control
- Vol. 53 (8) , 910
“Letter to the editor: Artificial intelligence (AI) use for personal protective equipment training, remediation, and education in health care”
- Open Access
- 1 July 2025
- Published by Wolters Kluwer Health in Annals of Clinical Cardiology
- Vol. 7 (2) , 122
Commentary on “Quantification and Correlation of Cardiac Troponins in High-risk Patients with Varying Severity of Positive Stress Lexiscan Myocardial Perfusion Imaging”
- 1 July 2025
- Published by Wolters Kluwer Health in Annals of Clinical Cardiology
- Vol. 7 (2) , 122
Open AccessCommentary on “Quantification and Correlation of Cardiac Troponins in High-risk Patients with Varying Severity of Positive Stress Lexiscan Myocardial Perfusion Imaging”